🇺🇸 FDA
Patent

US 10881660

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

granted A61KA61K31/513A61P

Quick answer

US patent 10881660 (Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/513, A61P, A61P1/16